Table 1.
The baseline clinical characteristics of MS patients.
| Variable | COVID-19 infection | P-value | ||
|---|---|---|---|---|
| Negative | Positive | |||
| Gender | Female (%) | 144 (71.28%) | 20 (9.9%) | 0.698 |
| Male (%) | 32 (15.84%) | 5 (2.47%) | ||
| Age (mean ± SD) | 38.09 ± 10.440 | 37.45 ± 8.768 | 0.095 | |
| MS course | CIS (%) | 4 (1.98%) | 1 (0.49%) | 0.306 |
| Primary-progressive (%) | 8 (3.96%) | 1 (0.49%) | ||
| Secondary progressive (%) | 39 (19.30%) | 4 (1.98%) | ||
| Relapsing-remitting (%) | 126 (62.37%) | 19 (0.49) | ||
| EDSS (mean) | 1.76 ± 1.65 | 1.77 ± 1.52 | 0.319 | |
| Comorbidity | Negative | 132 (65.34%) | 19 (9.40%) | 0.652 |
| Hypothyroidism | 19 (19.40%) | 6 (2.97%) | ||
| Hyperlipidemia | 10 (4.95%) | 0 (0.00%) | ||
| Hypertension | 8 (3.96%) | 0 (0.00%) | ||
| Diabetes mellitus | 6 (2.97%) | 0 (0.00%) | ||
| Others | 2 (0.99%) | 0 (0.00%) | ||
| SARS-CoV 2 IgG level | Positive | 22 (10.89%) | 4 (1.98%) | 0.24 |
| Negative | 155 (76.73%) | 21 (10.39%) | ||
MS: multiple sclerosis; CIS: clinically isolated syndrome; RRMS: relapse remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis; PPMS: primary progressive multiple sclerosis; EDSS: Expanded Disability Status Scale.